Abstract
Background:To evaluate whether the specific choroidal neovascularization(CNV)characteristics measured using optical coherence tomography angiography(OCTA)can predict the 6-month prognosis of neovascular age-related macular degeneration(nAMD)after anti-vascular endothelial growth factor(anti-VEGF)therapy.Methods:Patients with type 1,type 2,or mixed-type neovascularization(NV)were prospectively included.Partici-pants underwent an initial loading phase of three consecutive monthly intravitreal injections of Conbercept(0.5 mg)and were switched to a pro re nata(PRN)treatment strategy.OCTA images were evaluated for eyes that underwent follow-up assessments for more than 6 months.CNV lesions were manually segmented,and the CNV area,vessel area,greatest vascular caliber(GVC),and greatest linear dimension(GLD)were compared between responders and non-responders.Two masked graders independently measured the above-mentioned parameters using OCTA,and consistency was assessed using the intraclass correlation coefficient(ICC)values.Multiple logistic regression analysis was performed to evaluate the effect of a 3-month change in the CNV area,GLD,and GVC on the 6-month response to anti-VEGF agents.Results:Among the 60 eyes of 60 patients with nAMD,39 were responders and 21 were non-responders.The pro-portion of CNV types was significantly different between responders and non-responders(P=0.009).Patients with type 2 or mixed NV seemed more likely to respond to the treatment(28.2%vs.0.0%,and 30.8%vs.23.8%,respectively).The change in GVC showed a significant difference between responders(-4.98±17.17 pm)and non-responders(11.01±14.10 pm)after three monthly intravitreal anti-VEGF injections.Multiple logistic regression analysis showed that only the change in GVC remained significant after controlling for baseline GVC,injection number,and CNV type(adjusted OR=1.083;P=0.008).Conclusions:Type 2 and mixed-type NV were significantly associated with a better response to anti-VEGF therapy.Changes in GVC after 3 months of treatment were significantly associated with a response to anti-VEGF therapy at 6 months.
基金项目
Frontier Project of Hospital Development Center(SHDC12016105)
Clinical Research Innovation Team Project of Shanghai General Hospital(CTCCR-2016A02)
Scientific Project of Shanghai Municipal Health Commission(201940151)
Shanghai Collaborative Innovation Center for Translational Medicine(TM201917)
Shanghai Hospital Development Center(SHDC2020CR2040B)
Shanghai Hospital Development Center(SHDC2020CR5014)